Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics develops small molecule medicines for rare muscle diseases, based in Boulder, Colorado. It last closed at $42.04 on Nov 17, down 3.75% on the day. The average 12-month price target from 3 analysts is $56.00 (+33.2% from the last close), with a high of $60.00 and a low of $51.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in EWTX, 100% of them bullish and 0% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From EWTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on EWTX in the past 90 days. The average target is $56.00, with a high of $60.00 and a low of $51.00, compared with the last close of $42.04.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | Wedbush | Target lowered | Buy | $52 → $51 |
| Sep 21 | HC Wainwright & Co. | Target raised | Buy | $45 → $57 |
| Aug 20 | JP Morgan | Maintained | Buy | $60 |
| Aug 11 | Goldman Sachs | Target raised | Hold | $32 → $36 |
| Jul 20 | Evercore ISI Group | Maintained | Buy | $55 |
Technical Analysis
The stock is 1% above its 20 day and 2% above its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 50). The nearest support is the swing low (Aug 14) at $41.98, and the nearest resistance the swing high (Sep 30) at $42.12.
| RSI (14) | 49.95 | Middle of its range | Neutral |
| MACD | 1.30 | Above its signal line | Bullish |
| Stochastic | 59.5 | Middle of its range | Neutral |
| ADX (14) | 21.4 | Weak trend | |
| Williams %R | -55.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 18.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +11.6% | Change over 10 sessions | Bullish |
| ATR (14) | $2.77 | Typical daily range, 6.6% of price |
| RSI (14) | 53.94 | Middle of its range | Neutral |
| MACD | 1.95 | Below its signal line | Bearish |
| Stochastic | 66.7 | Middle of its range | Neutral |
| ADX (14) | 40.0 | Trending up | |
| Williams %R | -51.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 37.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −5.3% | Change over 10 sessions | Bearish |
| ATR (14) | $4.83 | Typical daily range, 11.5% of price |
What happened before
See how EWTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How EWTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in EWTX in the last 90 days.
EWTX Institutional Ownership
Full report →- ▲145 buying vs 92 selling
- ▲Held by funds +5.3 pts
- ▲Funds holding +27
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 253 | 226 | +11.9% |
| In funds' top 10 | 15 | 13 | +15.4% |
| Held by funds | 114.2% | 108.9% | +5.3 pts |
| New / increased | 46 / 99 | 40 / 83 | +17.9% |
| Reduced / sold out | 71 / 21 | 72 / 26 | −6.1% |
| Put/call ratio | 0.87 | 0.49 | +77.1% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EWTX is in one of them and how their past EWTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered EWTX in an article yet. Here's the latest on the wider market.
About Edgewise Therapeutics
Edgewise Therapeutics is a biopharmaceutical company based in Boulder, Colorado, that develops small molecule medicines for serious muscle diseases. Its main candidates target rare muscular dystrophies, including Duchenne and Becker, and a heart condition called hypertrophic cardiomyopathy. The company uses its own drug discovery platform to find treatments that act on muscle tissue, and these candidates are still in clinical trials. It is developing the therapies for patients with these conditions and the physicians who treat them.
- Headquarters
- Boulder, CO


